Understanding the guidelines for treating HIV disease - includes patient information guide for medication schedules

In 1996 a panel of quicks convened by the International AIDS Society--USA issued fresh guidelines for treating human immunodeficiency virus (HIV) infection, which have newly been updated. Quantitative plasma HIV-1 RNA concentration (viral load) and [CD4sup+] lymphocyte horizontals are used to monitor disease progression, determine the ne to initiate antiretroviral treatment, monitor effectiveness of treatment and evaluate the ne to change medications. Multi-drug therapy with nucleoside analogs, nonnucleoside change to the opposite transcriptase inhibitors and protease inhibitors can deduction in measurable improvement in clinical issue in HIV-1 infected patients.

Advances in the treatment of human immunodeficiency virus A (HIV) disease have made the antiretroviral therapy guidelines issued in 1993 inapplicable to passing from hand to hand clinical decision making. A panel of prompts for the International AIDS Society-USA evolveed new recommendations that were quick in emergenciesed at the XI International colloquy on AIDS in Vancouver.[1] The panel addressed four issues: when to initiate therapy, which impressed signs of drugs to use, when to change therapy and which images of drugs to use when a change in therapy is indicated. not long ago updated, these recommendations represent rife thinking on the management of HIV disease.[2]

Viral Load Testing

In the past, [CD4sup+] lymphocyte reckons provided the basis for the initiation of antiretroviral treatment and were used to help define acquired immunodeficiency syndrome (AIDS). Although produc in high numbers in answer to HIV infection, [CD4.sup.+] lymphocyte are the principal targets for replication of the HIV-virus. The virus inscribes the cell through various receptors, replicates inside the solitary abode; squalid and kills the cell as the viral offspring burst the cell walls. to solicit other [CD4.sup.+] lymphocytes.[3] We now know that the [CD4sup+] lymphocyte is barely an intermediate variable in a chain of variables leading from viral replication to the exhibition of AIDS; measurement of the [CD4sup+] lymphocyte deem is only an indirect marker of antiretroviral therapy, a measurement of the relative production and destruction of [CD4sup+] small cavity population.

Viral load, a measurement of the even of circulating (plasma) HIV RNA, reported in copies through mL, is a direct reflection of ongoing viral replication. As in the same state [i]or[/i] condition it is superior to the [CD4sup+] lymphocyte account for predicting the rate of progression to disentanglement of AIDS and for monitoring the meanings of antiretroviral treatment. [CD4.sup.+] numbers assist decision making about prophylactic therapies against opportunistic infections, since they ponder the body's ability to fight on the farther side infection in general. Figure 1 illustrates the time course of HIV disease and the relative horizontals of circulating viral RNA and [CD4sup+] lymphocyte In general, as the amount of virus increases, the [CD4sup+] esteem decreases, although this inverse relationship is neither constant nor predictable. The on a level of HIV RNA can rise or fall often more quickly than the [CD4sup+] count

[Figure 1 ILLUSTRATION OMITTED]

During the initial infection, viral replication increases dramatically, then declines to a steady state during the chronic, asymptomatic phase of HIV illness The latter phase can last from month to years before the infection progresse to the symptomatic phase. The viral load in the chronic, asymptomatic period is fairly stable in each character but varies greatly from united person to another. The HIV RNA flat has been shown to have prognostic value in predicting disease progression and time to death: the higher the plain the faster the rate of progression.[4,5]

generally three assays are available for determining viral loads in HIV infection: (1) Branched DNA (bDNA; Quantiplex--manufactured from Chiron Therapeutics, Emeryville, Calif). This assay uses a signal amplification technique. After high-speed centrifugation, the virus releases its RNA. Specific probes bind the RNA and adhere it to a special plate. Following a series of hybridization paces multiple bDNA and alkaline phosphatase-labeled atoms bind to the immobilized HIV RNA. A single HIV RNA may bind up to 1755 alkaline phosphatase atoms greatly enhancing the detection signal. A chemiluminescent substrate is added; light emission is proportional to the amount of RNA at hand (2) Reverse transcriptase polymerase chain reaction (RT-PCR; Amplicor HIV-1 Monitor-manufactured on Roche Diagnostic Systems, Inc., Somerville, NJ) Viral RNA is overthrow transcribed into a double-stranded DNA atom The two strands are then separated, nucleotides are added and more double-stranded DNA indivisible particles are created. After a known number of copies are produc a known number of internal dominion government molecules are added, and the ratio of the detection signal to the internal standard detection signal is calculated. (3) Nucleic acid sequence-based amplification (NASBA--manufactured by the agency of Organon Teknika but not nevertheless commercially available). This assay is also a nucleic acid amplification mode but rather than amplifying DNA, as does the Amplicor HIV Monitor ordeal the NASBA assay amplifies RNA. The advantage of this assay is that it can measure viral loads in any tissue, not just plasma.